PODD:NSD-Insulet Corporation (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 223.96

Change

0.00 (0.00)%

Market Cap

USD 14.70B

Volume

0.29M

Average Target Price

USD 225.68 (+0.77%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Its Omnipod System comprise two devices: a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, and its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts. Address: 100 Nagog Park, Acton, MA, United States, 01720

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-26 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology, Inc

N/A

USD25.05B 14.49 68.43
LVGO Livongo Health, Inc

N/A

USD13.69B N/A N/A
ABMD Abiomed, Inc

N/A

USD12.00B 75.42 46.69
TNDM Tandem Diabetes Care, Inc

N/A

USD6.60B N/A N/A
BRKR Bruker Corporation

N/A

USD5.99B 36.51 18.69
SDC SmileDirectClub, Inc

N/A

USD3.99B N/A N/A
IART Integra LifeSciences Holdings ..

N/A

USD3.96B 160.06 27.46
WMGI Wright Medical Group N.V

N/A

USD3.95B N/A 62.99
NUVA NuVasive, Inc

N/A

USD2.56B 49.69 17.19
SWAV ShockWave Medical, Inc

N/A

USD2.44B N/A N/A

ETFs Containing PODD

Symbol Name Weight Mer Price(Change) Market Cap
SLIM The Obesity ETF 0.00 % 0.35 %

N/A

USD0.01B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 30.82% 76% C 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.82% 76% C 81% B-
Trailing 12 Months  
Capital Gain 36.68% 76% C 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 36.68% 76% C 78% C+
Trailing 5 Years  
Capital Gain 772.80% 98% A+ 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 772.80% 98% A+ 97% A+
Average Annual (5 Year Horizon)  
Capital Gain 58.20% N/A N/A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 58.20% N/A N/A 93% A
Risk Return Profile  
Volatility (Standard Deviation) 38.35% N/A N/A 34% F
Risk Adjusted Return 151.74% N/A N/A 98% A+
Market Capitalization 14.70B 99% A+ 95% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 773.39 5% F 2% F
Price/Book Ratio 25.24 6% F 4% F
Price / Cash Flow Ratio 149.42 5% F 2% F
EV/EBITDA 143.86 3% F 5% F
Management Effectiveness  
Return on Equity 4.45% 87% B+ 62% D-
Return on Invested Capital 5.33% 82% B- 62% D-
Return on Assets 3.36% 88% B+ 76% C
Debt to Equity Ratio 1,169.83% 2% F 1% F
Technical Ratios  
Short Ratio 6.57 30% F 24% F
Short Percent 6.04% 36% F 34% F
Beta 0.81 59% F 70% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.